Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer

Keyphrases

• Metastatic Colorectal Cancer (mCRC) 100%
• Liquid Biopsy 100%
• Resistance mutations 100%
• Anti-epidermal Growth Factor Receptor Therapy 100%
• Targeted Therapy 66%
• Colorectal Cancer Prevention 66%
• Lack of Response 33%
• Clinical Practice 33%
• Causes of Mortality 33%
• Response Prediction 33%
• Epidermal Growth Factor Receptor 33%
• Colorectal Cancer 33%
• Decision Algorithm 33%
• Survival Benefit 33%
• New Standards 33%
• Patients with Colorectal Cancer 33%
• Antiangiogenic Therapy 33%
• KRAS mutation 33%
• Consensus Molecular Subtypes 33%
• Resistance Acquisition 33%
• NRAS mutation 33%
• BRAF mutation 33%
• Molecular Heterogeneity 33%

Medicine and Dentistry

• Colorectal Cancer 100%
• Metastatic Colorectal Cancer 100%
• Anti-Epidermal Growth Factor Receptor 100%
• Resistance Mutation 100%
• Liquid Biopsy 100%
• Cancer Therapy 50%
• Targeted Therapy 50%
• Prevalence 25%
• Epidermal Growth Factor Receptor 25%
• Antiangiogenic Therapy 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Colorectal Cancer 100%
• Epidermal Growth Factor Receptor 100%
• Metastatic Colorectal Cancer 100%
• Prevalence 25%
• Antiangiogenic Therapy 25%